GAL and hepatocellular carcinoma: In conclusion, the successful construction of novel fusion protein PK5-RL-Gal-3C based on Gal-3C provides theoretical basis for their further clinical application in the treatment of HCC patients and offers new strategy for further exploring Gal-3 antagonist.